Address
London Bioscience Innovation Centre
2 Royal College Street
London, NW1 0NH
United Kingdom
Contact
Ajay Mistry+44(0)788 1811739
ajay.mistry@oppilotech.com
Website
Download PDF
Building a computational model of E.coli
Our whole cell computational model of E.coli is being utilised to reveal new biology, identify viable first-in-class targets and build a pipeline of novel antibacterial drugs.
Our modelling approach is different from others in that we go into much higher level of detail allowing us to identify non-intuitive drug targets.
Technology:
Microorganisms:
Application:
Development stage:
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- CARB-X
- FIND
- GARDP
- REPAIR
- OTHER / NA
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
Pharma/Biotechs/Academic institutes
Oppilotech develops first-in-class antibacterial drugs – the drug targets are identified using a platform based on systems biology and ML
Oppilotech have built up a bacterial isolate collection and also undertake microbiology services (MIC, MBC testing, Time/Kill Post Antibiotic Effect Analysis & Serial Passage/Mutation Frequency Testing) for clients developing antibacterial products
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!